• Accredited 12-credit programme will build health informatics capabilities among ICLDEC staff.
  • Collaboration will give RIT Dubai students opportunities to engage with healthcare challenges and gain practical experience.

ABU DHABI, 29 October 2026 – Imperial College London Diabetes & Endocrine Centre (ICLDEC), part of M42, and Rochester Institute of Technology Dubai (RIT Dubai) have signed a Memorandum of Understanding (MoU) to equip healthcare professionals with the data and technology skills increasingly required in clinical practice. Signed at the Abu Dhabi Future Health Summit (ADFHS), the MoU will begin with an accredited health informatics programme for ICLDEC staff and connect academic learning with operational healthcare challenges.

The agreement reflects the growing opportunity to strengthen professional development as data and digital tools become more integrated into clinical practice. By bringing clinical and academic expertise together, ICLDEC and RIT Dubai aim to make professional education more relevant to the realities of modern healthcare.

The first area of collaboration will see ICLDEC staff participate in RIT Dubai’s Credit-Bearing Micro-Credential in Health Informatics. Accredited by the UAE Ministry of Education, the 12-credit programme will help participants develop skills in using data and digital technologies in healthcare. The curriculum will draw on operational and technology challenges encountered by healthcare teams, giving participants opportunities to apply their learning to issues relevant to their work.

Dr. Mai Al Jaber, Chief Executive Officer of ICLDEC, said: “As data and digital technologies play a greater role in healthcare, our teams need the skills to use them effectively in their day-to-day work. This partnership gives our people access to structured health informatics training that is directly connected to the challenges they encounter in clinical and operational settings. It will help us build capabilities that support better decision-making and care delivery.”

Under the collaboration, ICLDEC will bring insight into clinical, operational and technology needs, while RIT Dubai will contribute academic expertise, learning resources and facilities. These healthcare challenges may also inform student projects, giving RIT Dubai students opportunities to work on practical problems and giving ICLDEC access to academic perspectives on potential solutions.

Dr. Yousef Al Assaf, President of RIT Dubai, said: “The UAE’s healthcare future depends on professionals who are as comfortable with data and digital tools as they are with patients. Through this MoU, RIT Dubai will bring its applied, technology-driven approach to ICLDEC’s teams, starting with our accredited health informatics programme, which will help participants find innovative solutions to real problems encountered in their own work. It will also keep our case studies anchored in the day-to-day realities of healthcare and give our students the chance to tackle challenges that matter in Abu Dhabi and beyond.”

The MoU also provides a framework for ICLDEC and RIT Dubai to explore healthcare-focused capstone projects, internships for RIT Dubai students, knowledge-sharing and further joint education initiatives.

By connecting education with clinical practice, ICLDEC and RIT Dubai aim to turn shared expertise into practical outcomes: stronger professional development, more relevant experience for students and new approaches to the challenges shaping healthcare delivery.

-ENDS-

Notes to editors

About Imperial College London Diabetes & Endocrine Centre

Imperial College London Diabetes & Endocrine Centre (ICLDEC), an M42 company, is a state-of-the-art outpatient facility that specialises in treatment, research, training, and public health awareness for diabetes and endocrine-related health conditions. Over the last 2 decades, the Centre has gained international renown for its holistic approach to the treatment of diabetes and related complications that enables patients to receive the full spectrum of care they need in one place.

With more than 70 diabetes professionals and endocrinologists under one roof, Imperial College London Diabetes & Endocrine Centre offers best-in-class medical attention from first diagnosis to disease management across 11 specialist practice areas including adult and paediatric endocrinology, treatment of metabolic and electrolyte disorders, pre- and post-bariatric surgery care, heart disease prevention, nutritional advice, diabetes education services, ophthalmology, nephrology, and podiatry.

ICLDEC was established in 2006 in Abu Dhabi by Mubadala in partnership with the UK’s Imperial College London to address the growing demand for diabetes care in the UAE. The centre now operates four branches across Abu Dhabi, Al Dhafra and Al Ain, touching the lives of more than one million people through patient-centric programmes and public health initiatives. In 2007, ICLDEC launched Diabetes. Knowledge. Action, now the longest running public health awareness campaign in the country. The initiative promotes an active lifestyle through an ongoing calendar of events for the whole community.

ICLDEC holds the Joint Commission International (JCI) Clinical Care Program Certification in Outpatient Diabetes Management and JCI Accreditation for Ambulatory Care.

For more information, please visit www.icldec.ae

About M42

M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally.

Established in 2023, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.